Clal Biotechnology Industries Ltd. (TASE: CBI) today announced that Sight Diagnostics, a portfolio company of Anatomy, Clal Biotechnology’s investment fund for medical devices, had raised $28 million. When the round is completed, Anatomy’s stake in Sight Diagnostics will be 7%. Clal Biotechnology holds 50% of Anatomy.
Clal Biotechnology’s share price fell 8% today, despite the announcement, pushing its market cap down to NIS 425 million. Today’s drop is probably a result of falls in the US biotech market, also reflected in the share prices of public companies in which Clal Biotechnology has holdings: Gamida Cell Ltd. (Nasdaq: GMDA), MediWound Ltd, (Nasdaq: MDWD), and Neon Therapeutics (NasdaNTGN).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.